IRIST Logo Articles and Publications
Nuclear Links
About Us
News and EventsArticles and PublicationsConventions and CongressesNewslettersIndustry News
Forum
Atlas
Useful Links
Contact Us
  1. Postoperative Strontium-90 Brachytherapy in the Prevention of Keloids: Results and Prognostic Factors.
    Viani, Stefano, Afonso, De Fendi,
    Int J Radiat Oncol Biol Phys, PMID: 19101094

  2. Particle size analysis: 90Y and 99mTc-labelled colloids.
    Jankovi, ć, D; Maksin, T; Djoki, ć, D; Milonji, ć, S; Nikoli, ć, N; Mirkovi, ć, M; Vranjes-Djuri, ć, S;
    J Microsc, PMID: 19094046

  3. Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1.
    Oei, Ang; èle L M; Sweep, Fred C G J; Geurts-Moespot, Anneke; van Tienoven, Doorl; ène; Von Mensdorff-Pouilly, Silvia; Thomas, Chris M G; Massuger, Leon F A G;
    Anticancer Res, PMID: 19035301

  4. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme.
    Veeravagu, Anand; Liu, Zhaofei; Niu, Gang; Chen, Kai; Jia, Bing; Cai, Weibo; Jin, Cunjing; Hsu, Andrew R; Connolly, Andrew J; Tse, Victor; Wang, Fan; Chen, Xiaoyuan;
    Clin Cancer Res, PMID: 19010848

  5. Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan.
    Baechler, S; ébastien; Hobbs, Robert F; Prideaux, Andrew R; Recordon, M; élanie; Bischof-Delaloye, Angelika; Sgouros, George;
    Cancer Biother Radiopharm, PMID: 18999935

  6. [Genetic aspects of longevity and aging.]
    Kakauridze, N; Guchua, E; Mgebrishvili, M;
    Georgian Med News, PMID: 18997259

  7. Radiation emission dose from patients administered 90Y-labelled radiopharmaceuticals: comparison of experimental measurements versus Monte Carlo simulation.
    Meo, Sergio Lo; Cicoria, Gianfranco; Montini, Giancarlo; Bergamini, Carlo; Campanella, Francesco; Pancaldi, Davide; Panebianco, Antonio Sabatino; Rubello, Domenico; Marengo, Mario;
    Nucl Med Commun, PMID: 18987532

  8. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.
    Jacobs, Samuel A; Swerdlow, Steven H; Kant, Jeffrey; Foon, Kenneth A; Jankowitz, Rachel; Land, Stephanie R; DeMonaco, Nicholas; Joyce, Judith; Osborn, Jennifer L; Evans, Terry L; Schaefer, Patricia M; Luong, The Minh;
    Clin Cancer Res, PMID: 18981007

  9. Complexation and biodistribution study of 111In and 90Y complexes of bifunctional phosphinic acid analogs of H4dota.
    F, örsterová, Michaela; Petr, ík, Milos; L, áznicková, Alice; L, áznícek, Milan; Hermann, Petr; Lukes, Ivan; Melichar, Frantisek;
    Appl Radiat Isot, PMID: 18951809

  10. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging.
    Wei, Liu H; Olafsen, Tove; Radu, Caius; Hildebrandt, Isabel J; McCoy, Mark R; Phelps, Michael E; Meares, Claude; Wu, Anna M; Czernin, Johannes; Weber, Wolfgang A;
    J Nucl Med, PMID: 18927335

  11. 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging.
    Iagaru, Andrei; Gambhir, Sanjiv Sam; Goris, Michael L;
    J Nucl Med, PMID: 18927323

  12. Post-mortem considerations of Yttrium-90 90Y microsphere therapy procedures.
    Nelson, Kevin; Vause, Paul E; Koropova, Polina;
    Health Phys, PMID: 18849708

  13. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
    Mattes, M Jules; Sharkey, Robert M; Karacay, Habibe; Czuczman, Myron S; Goldenberg, David M;
    Clin Cancer Res, PMID: 18829494

  14. Cure of neuroendocrine carcinoma by peptide receptor radionuclide therapy.
    Z, öphel, Klaus; Strumpf, Annette; Wunderlich, Gerd; Oehme, Liane; Eisenhofer, Graeme; Kotzerke, Joerg;
    Clin Nucl Med, PMID: 18806569

  15. Radiologic findings following Y90 radioembolization for primary liver malignancies.
    Ibrahim, Nikolaidis, Miller, Lewandowski, Ryu, Sato, Senthilnathan, Riaz, Kulik, Mulcahy, Omary, Salem,
    Abdom Imaging, PMID: 18777189

  16. Yttrium-90 microsphere induced gastrointestinal tract ulceration.
    South, Christopher D; Meyer, Marty M; Meis, Gregory; Kim, Edward Y; Thomas, Fred B; Rikabi, Ali A; Khabiri, Hooman; Bloomston, Mark;
    World J Surg Oncol, PMID: 18764938

  17. Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation.
    Dahle, Jostein; Bruland, Oyvind S; Larsen, Roy H;
    Int J Radiat Oncol Biol Phys, PMID: 18722269

  18. Beta radiation exposure of staff during and after therapies with 90Y-labelled substances.
    Rimpler, A; Barth, I; Baum, R B; Senftleben, S; Geworski, L;
    Radiat Prot Dosimetry, PMID: 18718959

  19. Pigmented villonodular synovitis managed by Yttrium 90 after debulking surgery.
    Ozturk, Hayati; Bulut, Okay; Oztemur, Zekeriya; Bulut, Sema;
    Saudi Med J, PMID: 18690320

  20. Gateways to clinical trials.
    Tomillero, A; Moral, M A;
    Methods Find Exp Clin Pharmacol, PMID: 18597009

  21. Severe coagulopathy after 90Y microsphere administration: resemblance to the Kasabach-Merritt syndrome.
    Hoffman, Mark A; Rubin, Jason I; Vinceguerra, Vincent P; Nowakowski, F Scott; Warner, Richard R P;
    J Vasc Interv Radiol, PMID: 18589326

  22. Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children.
    O'Dorisio, M Sue; Khanna, Geetika; Bushnell, David;
    Cancer Metastasis Rev, PMID: 18581060

  23. Apoferritin-templated yttrium phosphate nanoparticle conjugates for radioimmunotherapy of cancers.
    Wu, Hong; Wang, Jun; Wang, Zhemin; Fisher, Darrell R; Lin, Yuehe;
    J Nanosci Nanotechnol, PMID: 18572643

  24. Gateways to clinical trials.
    Moral, M A; Tomillero, A;
    Methods Find Exp Clin Pharmacol, PMID: 18560631

  25. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
    Pandit-Taskar, Neeta; O'Donoghue, Joseph A; Morris, Michael J; Wills, Eze A; Schwartz, Lawrence H; Gonen, Mithat; Scher, Howard I; Larson, Steven M; Divgi, Chaitanya R;
    J Nucl Med, PMID: 18552139

  26. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
    Kennedy, Andrew S; Dezarn, William A; McNeillie, Patrick; Coldwell, Doug; Nutting, Charles; Carter, Dennis; Murthy, Ravi; Rose, Steven; Warner, Richard R P; Liu, David; Palmedo, Holger; Overton, Carroll; Jones, Bonita; Salem, Riad;
    Am J Clin Oncol, PMID: 18525307

  27. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.
    Rhee, Thomas K; Lewandowski, Robert J; Liu, David M; Mulcahy, Mary F; Takahashi, Gary; Hansen, Paul D; Benson, Al B; Kennedy, Andrew S; Omary, Reed A; Salem, Riad;
    Ann Surg, PMID: 18520231

  28. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Miederer, Matthias; Henriksen, Gjermund; Alke, Andrea; Mossbrugger, Ilona; Quintanilla-Martinez, Leticia; Senekowitsch-Schmidtke, Reingard; Essler, Markus;
    Clin Cancer Res, PMID: 18519789

  29. [Neuroendocrine carcinoma of the breast. Our experience and a proposal of a therapeutic algorithm for a rare tumor]
    Scaramuzzi, G; Murgo, R M; Cuttitta, A; Ciuffreda, L;
    G Chir, PMID: 18507954

  30. alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.
    Yoshimoto, Mitsuyoshi; Ogawa, Kazuma; Washiyama, Kohshin; Shikano, Naoto; Mori, Hirofumi; Amano, Ryohei; Kawai, Keiichi;
    Int J Cancer, PMID: 18498129

  31. Technical note: the calibration of 90Y-labeled SIR-Spheres using a nondestructive spectroscopic assay.
    Selwyn, R; Micka, J; DeWerd, L; Nickles, R; Thomadsen, B;
    Med Phys, PMID: 18491520

  32. Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.
    Pulcrano, M; Camera, L; Pagano, L; Del Vecchio, S; Ferone, D; Bodei, L; Murgia, A; Pace, L; Storto, G; Paganelli, G; Colao, A; Salvatore, M; Lombardi, G; Biondi, B;
    J Endocrinol Invest, PMID: 18475055

  33. Biliary sequelae following radioembolization with Yttrium-90 microspheres.
    Atassi, Bassel; Bangash, Affaan K; Lewandowski, Robert J; Ibrahim, Saad; Kulik, Laura; Mulcahy, Mary F; Murthy, Ravi; Ryu, Robert K; Sato, Kent T; Miller, Frank H; Omary, Reed A; Salem, Riad;
    J Vasc Interv Radiol, PMID: 18440457

  34. Radioembolization in patients with hepatic metastases from breast cancer.
    Jakobs, Tobias F; Hoffmann, Ralf-Thorsten; Fischer, Ton; Stemmler, Hans-Joachim; Tatsch, Klaus; La Fougere, Christian; Murthy, Ravi; Reiser, Maximillian F; Helmberger, Thomas K;
    J Vasc Interv Radiol, PMID: 18440456

  35. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.
    Bodei, Lisa; Cremonesi, Marta; Ferrari, Mahila; Pacifici, Monica; Grana, Chiara M; Bartolomei, Mirco; Baio, Silvia M; Sansovini, Maddalena; Paganelli, Giovanni;
    Eur J Nucl Med Mol Imaging, PMID: 18427807

  36. [Effectiveness evaluation of knee joint 90Y radiosynovectomy]
    Miszczyk, Leszek; Wozniak, Grzegorz; Jochymek, Bozena; Spindel, Jerzy; Wygoda, Zbigniew;
    Przegl Lek, PMID: 18409343

  37. Radiation therapy and biological compounds for consolidation therapy in advanced ovarian cancer.
    Auranen, A; Gr, énman, S;
    Int J Gynecol Cancer, PMID: 18336400

  38. Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
    Otte, Andreas;
    Hell J Nucl Med, PMID: 18392220

  39. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.
    Ibrahim, Saad-M; Lewandowski, Robert-J; Sato, Kent-T; Gates, Vanessa-L; Kulik, Laura; Mulcahy, Mary-F; Ryu, Robert-K; Omary, Reed-A; Salem, Riad;
    World J Gastroenterol, PMID: 18350597

  40. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival.
    Sato, Kent T; Lewandowski, Robert J; Mulcahy, Mary F; Atassi, Bassel; Ryu, Robert K; Gates, Vanessa L; Nemcek, Albert A; Barakat, Omar; Benson, Al; Mandal, Robert; Talamonti, Mark; Wong, Ching-Yee O; Miller, Frank H; Newman, Steven B; Shaw, John M; Thurston, Kenneth G; Omary, Reed A; Salem, Riad;
    Radiology, PMID: 18349311

  41. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
    Zinzani, Pier Luigi; Tani, Monica; Pulsoni, Alessandro; Gobbi, Marco; Perotti, Alessio; De Luca, Stefano; Fabbri, Alberto; Zaccaria, Alfonso; Voso, Maria Teresa; Fattori, Pierpaolo; Guardigni, Luciano; Ronconi, Sonia; Cabras, Maria Giuseppina; Rigacci, Luigi; De Renzo, Amalia; Marchi, Enrica; Stefoni, Vittorio; Fina, Mariapaola; Pellegrini, Cinzia; Musuraca, Gerardo; Derenzini, Enrico; Pileri, Stefano; Fanti, Stefano; Piccaluga, Pier Paolo; Baccarani, Michele;
    Lancet Oncol, PMID: 18342572

  42. Labeling, characterization, and in vivo localization of a new 90Y-based phosphonate chelate 2,3-dicarboxypropane-1,1-diphosphonic acid for the treatment of bone metastases: Comparison with 99mTc-DPD complex.
    Djoki, ć, Divna Dj; Jankovi, ć, Drina Lj; Nikoli, ć, Nadezda S;
    Bioorg Med Chem, PMID: 18331797

  43. [Application of radiometallic compounds for medical diagnosis and therapy]
    Saji, Hideo;
    Yakugaku Zasshi, PMID: 18311050

  44. Multidisciplinary approach including receptor radionuclide therapy with 90Y-DOTATOC ([90Y-DOTA0, Tyr3]-octreotide) and 177Lu-DOTATATE ([177Lu-DOTA0, Tyr3]-octreotate) in ectopic cushing syndrome from a metastatic gastrinoma: a promising proposal.
    Dav, ì, Maria Vittoria; Bodei, Lisa; Ferdeghini, Marco; Falconi, Massimo; Testoni, Marco; Paganelli, Giovanni; Oliani, Cristina; Lo Cascio, Vincenzo; Francia, Giuseppe;
    Endocr Pract, PMID: 18308661

  45. Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma.
    Assi, é, Karine; Dieudonn, é, Arnaud; Gardin, Isabelle; Buvat, Ir; ène; Tilly, Herv; é; Vera, Pierre;
    Cancer Biother Radiopharm, PMID: 18298329

  46. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell, Roland; Dietlein, Markus; Schom, äcker, Klaus; Kobe, Carsten; Borchmann, Peter; Schicha, Harald; Hallek, Michael; Engert, Andreas;
    Onkologie, PMID: 18268399

  47. Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography.
    Bodet-Milin, Caroline; Kraeber-Bod, éré, Fran; çoise; Dupas, Beno; ît; Morschhauser, Franck; Gastinne, Thomas; Le Gouill, Steven; Campion, Lo; ïc; Harousseau, Jean-Luc; Wegener, William A; Goldenberg, David M; Huglo, Damien;
    Haematologica, PMID: 18268287

  48. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
    Ulaner, Gary A; Colletti, Patrick M; Conti, Peter S;
    Radiology, PMID: 18258810

  49. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay.
    Atassi, Bassel; Bangash, Affaan K; Bahrani, Ammar; Pizzi, Giuseppi; Lewandowski, Robert J; Ryu, Robert K; Sato, Kent T; Gates, Vanessa L; Mulcahy, Mary F; Kulik, Laura; Miller, Frank; Yaghmai, Vahid; Murthy, Ravi; Larson, Andrew; Omary, Reed A; Salem, Riad;
    Radiographics, PMID: 18203932

  50. Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop.
    Zinzani, Pier Luigi; d'Amore, Francesco; Bombardieri, Emilio; Brammer, Caroline; Codina, Jos; é Gómez; Illidge, Tim; Jurczak, Wojciech; Linkesch, Werner; Morschhauser, Franck; Vandenberghe, Elisabeth; Van Hoof, Achiel;
    Eur J Cancer, PMID: 18194857

  51. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.
    Zinzani, Pier Luigi; Tani, Monica; Fanti, Stefano; Stefoni, Vittorio; Musuraca, Gerardo; Vitolo, Umberto; Perrotti, Alessio; Fina, Mariapaola; Derenzini, Enrico; Baccarani, Michele;
    Cancer, PMID: 18189293

  52. Extraction paper chromatography technique for the radionuclidic purity evaluation of 90Y for clinical use.
    Pandey, Usha; Dhami, Prem S; Jagesia, Poonam; Venkatesh, Meera; Pillai, M R A;
    Anal Chem, PMID: 18173248

  53. In vitro and ex vivo storage phosphor imaging of short-living radioisotopes.
    Knol, Remco J J; de Bruin, Kora; de Jong, Jan; van Eck-Smit, Berthe L F; Booij, Jan;
    J Neurosci Methods, PMID: 18164072

  54. Evaluation of different beta-counting systems involved in 90Y-Zevalin quality control.
    Urbano, Nicoletta; Modoni, Sergio;
    Nucl Med Commun, PMID: 18090222

  55. Dose calculation formalisms and consensus dosimetry parameters for intravascular brachytherapy dosimetry: recommendations of the AAPM Therapy Physics Committee Task Group No. 149.
    Chiu-Tsao, Sou-Tung; Schaart, Dennis R; Soares, Christopher G; Nath, Ravinder;
    Med Phys, PMID: 18072478

  56. 18F-labeled resin microspheres as surrogates for 90Y resin microspheres used in the treatment of hepatic tumors: a radiolabeling and PET validation study.
    Selwyn, R G; Avila-Rodriguez, M A; Converse, A K; Hampel, J A; Jaskowiak, C J; McDermott, J C; Warner, T F; Nickles, R J; Thomadsen, B R;
    Phys Med Biol, PMID: 18065846

  57. Hepatic yttrium-90 radioembolotherapy in metastatic colorectal cancer treated with cetuximab or bevacizumab.
    Murthy, Ravi; Eng, Cathy; Krishnan, Sunil; Madoff, David C; Habbu, Amit; Canet, Sara; Hicks, Marshall E;
    J Vasc Interv Radiol, PMID: 18057297

  58. Gateways to clinical trials.
    Bayes, M; Rabasseda, X; Prous, J R;
    Methods Find Exp Clin Pharmacol, PMID: 18040531

  59. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis.
    Kulik, Laura M; Carr, Brian I; Mulcahy, Mary F; Lewandowski, Robert J; Atassi, Bassel; Ryu, Robert K; Sato, Kent T; Benson, Al; Nemcek, Albert A; Gates, Vanessa L; Abecassis, Michael; Omary, Reed A; Salem, Riad;
    Hepatology, PMID: 18027884

  60. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
    Krishnan, Amrita; Nademanee, Auayporn; Fung, Henry C; Raubitschek, Andrew A; Molina, Arturo; Yamauchi, Dave; Rodriguez, Roberto; Spielberger, Ricardo T; Falk, Peter; Palmer, Joycelynne M; Forman, Stephen J;
    J Clin Oncol, PMID: 18025438

  61. Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
    Wiseman, Gregory A; Conti, Peter S; Vo, Katie; Schilder, Russell J; Gordon, Leo I; Emmanouilides, Christos; Silverman, Dan H; Witzig, Thomas E; Darif, Mohamed; Molina, Arturo;
    Clin Lymphoma Myeloma, PMID: 18021468

  62. [Clinical use of nuclear medicine in the management of thyroid diseases]
    Endo, Keigo;
    Nippon Rinsho, PMID: 18018563

  63. Response to [90Yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: a phase II clinical trial.
    Iten, Fabienne; M, üller, Beat; Schindler, Christian; Rochlitz, Christoph; Oertli, Daniel; M, äcke, Helmut R; M, üller-Brand, Jan; Walter, Martin A;
    Clin Cancer Res, PMID: 18006770

  64. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres.
    Gulec, Seza A; Siegel, Jeffry A;
    J Nucl Med, PMID: 18006608

  65. Radioembolization with 90Y microspheres: technical considerations.
    Salem, Riad;
    J Vasc Interv Radiol, PMID: 18004003

  66. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma.
    Young, Joseph Y; Rhee, Thomas K; Atassi, Bassel; Gates, Vanessa L; Kulik, Laura; Mulcahy, Mary F; Larson, Andrew C; Ryu, Robert K; Sato, Kent T; Lewandowski, Robert J; Omary, Reed A; Salem, Riad;
    J Vasc Interv Radiol, PMID: 18003987

  67. Colour quenching corrections on the measurement of 90Sr through Cerenkov counting.
    Mosqueda, F; Villa, M; Vaca, F; Bol, ívar, J P;
    Anal Chim Acta, PMID: 17996541

  68. Technical aspects of radioembolization with 90Y microspheres.
    Salem, Riad; Lewandowski, Robert J; Sato, Kent T; Atassi, Bassel; Ryu, Robert K; Ibrahim, Saad; Nemcek, Albert A; Omary, Reed A; Madoff, David C; Murthy, Ravi;
    Tech Vasc Interv Radiol, PMID: 17980315

  69. High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas.
    Ferrucci, Pier F; Vanazzi, Anna; Grana, Chiara M; Cremonesi, Marta; Bartolomei, Mirco; Chinol, Marco; Ferrari, Mahila; Radice, Davide; Papi, Stefano; Martinelli, Giovanni; Paganelli, Giovanni;
    Br J Haematol, PMID: 17979944

  70. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment.
    Cremonesi, Marta; Ferrari, Mahila; Grana, Chiara Maria; Vanazzi, Anna; Stabin, Mike; Bartolomei, Mirco; Papi, Stefano; Prisco, Gennaro; Ferrucci, Pier Francesco; Martinelli, Giovanni; Paganelli, Giovanni;
    J Nucl Med, PMID: 17978355

  71. 90Yttrium microspheres for nonresectable liver cancer: the University of Connecticut Health Center experience.
    Rowe, Bryan P; Weiner, Ronald; Foster, John; Dowsett, Robert;
    Conn Med, PMID: 17966721

  72. Preparation and evaluation of a new radiopharmaceutical for radiosynovectomy, 111Ag-labelled hydroxyapatite (HA) particles.
    Chattopadhyay, Sankha; Vimalnath, K V; Saha, Sujata; Korde, Aruna; Sarma, H D; Pal, Sujit; Das, Malay K;
    Appl Radiat Isot, PMID: 17951062

  73. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
    Jacene, Heather A; Filice, Ross; Kasecamp, Wayne; Wahl, Richard L;
    J Nucl Med, PMID: 17942813

  74. A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States.
    Schultz, Michael K; Cessna, Jeffrey T; Anderson, Tamara L; Ponto, James A; Petry, Neil; Kowalsky, Richard J; Palmer, Matthew R; Beinlich, Uwe F; Baker, William; Hinkle, George H; Hung, Joseph C; Quinton, Timothy; Rice, Peter A; Divgi, Chaitanya; Norenberg, Jeffrey P;
    Appl Radiat Isot, PMID: 17933545

  75. Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma.
    Iwamoto, Fabio M; Schwartz, Jazmin; Pandit-Taskar, Neeta; Peak, Scott; Divgi, Chaitanya R; Zelenetz, Andrew D; Humm, John; Abrey, Lauren E;
    Cancer, PMID: 17932895

  76. Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles.
    Nuttens, V E; W, éra, A-C; Bouchat, V; Lucas, S;
    Appl Radiat Isot, PMID: 17913502

  77. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies.
    Park, Steven I; Press, Oliver W;
    Curr Opin Hematol, PMID: 17898567

  78. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
    Cooney-Qualter, Erin; Krailo, Mark; Angiolillo, Anne; Fawwaz, Rashid A; Wiseman, Gregory; Harrison, Lauren; Kohl, Virginia; Adamson, Peter C; Ayello, Janet; vande Ven, Carmella; Perkins, Sherrie L; Cairo, Mitchell S;
    Clin Cancer Res, PMID: 17875803

  79. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer.
    Paganelli, Giovanni; Ferrari, Mahila; Ravasi, Laura; Cremonesi, Marta; De Cicco, Concetta; Galimberti, Viviana; Sivolapenko, Gregory; Luini, Alberto; De Santis, Rita; Travaini, Laura Lavinia; Fiorenza, Maurizio; Chinol, Marco; Papi, Stefano; Zanna, Claudio; Carminati, Paolo; Veronesi, Umberto;
    Clin Cancer Res, PMID: 17875802

  80. Yttrium-90 microspheres (TheraSphere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma.
    Allison, C;
    Issues Emerg Health Technol, PMID: 17824141

  81. Selecting an intervention time for intravascular enzymatic cleavage of peptide linkers to clear radioisotope from normal tissues.
    Siantar, Christine L Hartmann; DeNardo, Gerald L; Lam, Kit; Yuan, Aina; Daly, Thomas; DeNardo, Sally J;
    Cancer Biother Radiopharm, PMID: 17803451

  82. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
    Schillaci, Orazio; DeNardo, Gerald L; DeNardo, Sally J; Goldstein, Desiree S; Kroger, Linda A; O'Donnell, Robert T; Lamborn, Kathleen R;
    Cancer Biother Radiopharm, PMID: 17803447

  83. Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer.
    Oei, Ang; èle L M; Massuger, Leon F A G; Oyen, Wim J G;
    Cancer Biother Radiopharm, PMID: 17803445

  84. Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody.
    Vallera, Daniel A; Sicheneder, Andy R; Taras, Elizabeth P; Brechbiel, Martin W; Vallera, Jesse A; Panoskaltsis-Mortari, Angela; Burns, Linda J;
    Cancer Biother Radiopharm, PMID: 17803443

  85. Environmental, health and safety assessment of decommissioning radioisotope thermoelectric generators (RTGs) in northwest Russia.
    Standring, W J F; Dowdall, M; Sneve, M; Selnaes, Ø G; Amundsen, I;
    J Radiol Prot, PMID: 17768331

  86. Retreatment with 90Y-labelled ibritumomab tiuxetan in a patient with follicular lymphoma who had previously responded to treatment.
    Peyrade, Frederic; Italiano, Antoine; Fontana, Xavier; Peyrottes, Isabelle; Thyss, Antoine;
    Lancet Oncol, PMID: 17765194

  87. Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody.
    Decaudin, Didier; Levy, Rapha; ël; Lokiec, Fran; çois; Morschhauser, Franck; Djeridane, Malika; Kadouche, Jean; Pecking, Alain;
    Anticancer Drugs, PMID: 17762404

  88. [Ten years since the successful introduction of the first monoclonal antibody (rituximab) into the therapy of lymphomas]
    Trnen, ý, M; Klener, P;
    Cas Lek Cesk, PMID: 17722844

  89. Dose perturbation caused by stents: experiments with a model 90Sr/90Y source.
    Wilczek, Krzysztof; Petelenz, Barbara; Strza, Å‚a, Alicja; Marczewska, Barbara; Traczyk, Marek; Polo, Å„ski, Lech;
    Cardiovasc Intervent Radiol, PMID: 17710473

  90. Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report.
    Papajik, Tomas; Prochazka, Vit; Raida, Ludek; Kubova, Zuzana; Myslivecek, Miroslav; Drymlova, Jaroslava; Buriankova, Eva; Kucerova, Ladislava; Indrak, Karel;
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, PMID: 17690751

  91. Colloidal 90Y used for radiation synovectomy decreases the viability of chondrocytes in human cadaveric samples.
    Brecelj, Janez; Gmeiner-Stopar, Tanja; Jevsek, Marko; Bole, Velimir; Drobnic, Matej;
    Nucl Med Commun, PMID: 17667749

  92. Resin 90Y microsphere activity measurements for liver brachytherapy.
    Dezarn, William A; Kennedy, Andrew S;
    Med Phys, PMID: 17654890

  93. Measurement of Bremsstrahlung as a practical alternative to use of a liquid scintillation counter for the assessment of low activities of 90Y.
    Sawyer, Laura J; Evans, Martyn J; Hiscock, Sarah C;
    Nucl Med Commun, PMID: 17625385

  94. Radiosynovectomy in the treatment of chronic exsudative arthritis.
    Luka, Krzysztof; Kr, ól, Pawe; ł; Cie, śla, Pawe; ł; Berent, Aleksandra;
    Ortop Traumatol Rehabil, PMID: 17611457

  95. Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab.
    Fietz, Thomas; Thiel, Eckhard;
    Recent Results Cancer Res, PMID: 17607923

  96. Radiosynoviorthesis of knees by means of 166Ho-holmium-boro-macroaggregates.
    Kraft, Otakar; Kasp, árek, Richard; Ullmann, Vojtech; Melichar, Frantisek; Krop, ácek, Martin; Mirzajevova, Marcela;
    Cancer Biother Radiopharm, PMID: 17600479

  97. Translation of dosimetric results of preclinical radionuclide therapy to clinical situations: influence of photon irradiation.
    Uusij, ärvi, Helena; Bernhardt, Peter; Forssell-Aronsson, Eva;
    Cancer Biother Radiopharm, PMID: 17600475

  98. Positron-emitting resin microspheres as surrogates of 90Y SIR-Spheres: a radiolabeling and stability study.
    Avila-Rodriguez, Miguel A; Selwyn, Reed G; Hampel, Joseph A; Thomadsen, Bruce R; Dejesus, Onofre T; Converse, Alexander K; Nickles, Robert J;
    Nucl Med Biol, PMID: 17591559

  99. Preparation and biological evaluation of 111In-, 177Lu- and 90Y-labeled DOTA analogues conjugated to B72.3.
    Mohsin, Huma; Fitzsimmons, Jonathan; Shelton, Tiffani; Hoffman, Timothy J; Cutler, Cathy S; Lewis, Michael R; Athey, Phillip S; Gulyas, Gyongyi; Kiefer, Garry E; Frank, R Keith; Simon, Jaime; Lever, Susan Z; Jurisson, Silvia S;
    Nucl Med Biol, PMID: 17591549

  100. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET.
    Lin, Michael; Shon, Ivan Ho; Wilson, Robert; D'Amours, Scott K; Schlaphoff, Glenn; Lin, Peter;
    Hepatogastroenterology, PMID: 17591090

  101. An inductively coupled plasma mass spectrometry method for the quantification of yttrium-antibody based drugs using stable isotope tracing.
    Ciavardelli, Domenico; D'Anniballe, Gaetano; Nano, Giuseppe; Martin, Franck; Federici, Giorgio; Sacchetta, Paolo; Di Ilio, Carmine; Urbani, Andrea;
    Rapid Commun Mass Spectrom, PMID: 17590870

  102. Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.
    Harris, Thomas D; Cheesman, Edward; Harris, Anthony R; Sachleben, Richard; Edwards, D Scott; Liu, Shuang; Bartis, Judit; Ellars, Charles; Onthank, Dave; Yalamanchili, Padmaja; Heminway, Stuart; Silva, Paula; Robinson, Simon; Lazewatsky, Joel; Rajopadhye, Milind; Barrett, John;
    Bioconjug Chem, PMID: 17579472

  103. Characteristics of a 85Kr beta-particle source applied in Series 1 reference irradiations of DIS-1 direct ion storage dosemeters.
    Hakanen, A T; Sipil, ä, P M; Sahla, T T;
    Radiat Prot Dosimetry, PMID: 17548464

  104. Radioembolization with 90Y microspheres: angiographic and technical considerations.
    Lewandowski, Robert J; Sato, Kent T; Atassi, Bassel; Ryu, Robert K; Nemcek, Albert A; Kulik, Laura; Geschwind, Jean-Francois; Murthy, Ravi; Rilling, William; Liu, David; Bester, Lourens; Bilbao, Jose Ignacio; Kennedy, Andrew S; Omary, Reed A; Salem, Riad;
    Cardiovasc Intervent Radiol, PMID: 17516113

  105. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival.
    Bangash, Affaan K; Atassi, Bassel; Kaklamani, Virginia; Rhee, Thomas K; Yu, Maurice; Lewandowski, Robert J; Sato, Kent T; Ryu, Robert K; Gates, Vanessa L; Newman, Steven; Mandal, Robert; Gradishar, William; Omary, Reed A; Salem, Riad;
    J Vasc Interv Radiol, PMID: 17494843

  106. Targeted transarterial therapy of Vx-2 rabbit liver tumor with Yttrium-90 labeled ferromagnetic particles using an external magnetic field.
    Kobeiter, Hicham; Georgiades, Christos S; Leakakos, Tina; Torbenson, Michael; Hong, Kelvin; Geschwind, Jean-Francois;
    Anticancer Res, PMID: 17465199

  107. First approach to radionuclide mixtures quantification by using plastic scintillators. Influence of the diameter of the plastic beads.
    Taranc, ón, A; Garc, ía, J F; Rauret, G;
    Anal Chim Acta, PMID: 17448349

  108. Correlation analysis reveals the emergence of coherence in the gene expression dynamics following system perturbation.
    Neretti, Nicola; Remondini, Daniel; Tatar, Marc; Sedivy, John M; Pierini, Michela; Mazzatti, Dawn; Powell, Jonathan; Franceschi, Claudio; Castellani, Gastrone C;
    BMC Bioinformatics, PMID: 17430560

  109. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
    Witzig, Thomas E; Molina, Arturo; Gordon, Leo I; Emmanouilides, Christos; Schilder, Russell J; Flinn, Ian W; Darif, Mohamed; Macklis, Roger; Vo, Katie; Wiseman, Gregory A;
    Cancer, PMID: 17380530

  110. Radiation synovectomy with 90Y colloid in the therapy of recurrent knee joint effusions in patients with inflammatory joint diseases.
    Chrapko, Beata; Zwolak, Robert; Nocu, Å„, Anna; Go, Å‚ebiewska, Renata; Majdan, Maria;
    Rheumatol Int, PMID: 17380335

  111. Reducing renal uptake of 111In-DOTATOC: a comparison among various basic amino acids.
    Lin, Yung-Chang; Hung, Guang-Uei; Luo, Tsai-Yueh; Tsai, Shih-Chuan; Sun, Shung-Shung; Hsia, Chien-Chung; Chen, Shu-Ling; Lin, Wan-Yu;
    Ann Nucl Med, PMID: 17373340

  112. Array-optimized composite pulse for excellent whole-brain homogeneity in high-field MRI.
    Collins, Christopher M; Wang, Zhangwei; Mao, Weihua; Fang, Jieming; Liu, Wanzhan; Smith, Michael B;
    Magn Reson Med, PMID: 17326169

  113. EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin).
    Tennvall, Jan; Fischer, Manfred; Bischof Delaloye, Angelika; Bombardieri, Emilio; Bodei, Lisa; Giammarile, Francesco; Lassmann, Michael; Oyen, Wim; Brans, Boudewijn;
    Eur J Nucl Med Mol Imaging, PMID: 17323056

  114. Pathological findings in cystic craniopharyngiomas after stereotactic intracavitary irradiation with yttrium-90 isotope.
    Szeifert, Gy; örgy T; B, álint, Katalin; Sipos, L; ászló; Sarker, Mainul H; Czirj, ák, S; ándor; Julow, Jen; ö;
    Prog Neurol Surg, PMID: 17317998

  115. Stereotactic intracavitary irradiation of cystic craniopharyngiomas with yttrium-90 isotope.
    Julow, Jen; ö; L, ányi, Ferenc; Hajda, M; árta; Szeifert, Gy; örgy T; Viola, Arp; ád; B, álint, Katalin; Ny, áry, Istv; án;
    Prog Neurol Surg, PMID: 17317997

  116. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET.
    Miller, Frank H; Keppke, Ana L; Reddy, Denise; Huang, Jie; Jin, Jianhua; Mulcahy, Mary F; Salem, Riad;
    AJR Am J Roentgenol, PMID: 17312068

  117. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres.
    Keppke, Ana L; Salem, Riad; Reddy, Denise; Huang, Jie; Jin, Jianhua; Larson, Andrew C; Miller, Frank H;
    AJR Am J Roentgenol, PMID: 17312067

  118. Radiographically identified necrosis after 90Y microsphere brachytherapy: a new standard for oncologic response assessment?
    Welsh, James S;
    AJR Am J Roentgenol, PMID: 17312066

  119. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma.
    Kamel, Ihab R; Reyes, Diane K; Liapi, Eleni; Bluemke, David A; Geschwind, Jean-Francois H;
    J Vasc Interv Radiol, PMID: 17296704

  120. Rapid screening of 90Sr activity in water and milk samples using Cherenkov radiation.
    Stamoulis, K C; Ioannides, K G; Karamanis, D T; Patiris, D C;
    J Environ Radioact, PMID: 17293016

  121. 99mTc-EDDA/HYNIC-octreotate in detection of atypical bronchial carcinoid.
    Hubalewska-Dydejczyk, A; Fr, öss-Baron, K; Go, łkowski, F; Sowa-Staszczak, A; Miko, łajczak, R; Huszno, B;
    Exp Clin Endocrinol Diabetes, PMID: 17286235

  122. Radioembolization with Yttrium-90 microspheres: review of an emerging treatment for liver tumors.
    Gates, Vanessa L; Atassi, Bassel; Lewandowski, Robert J; Ryu, Robert K; Sato, Kent T; Nemcek, Albert A; Omary, Reed; Salem, Riad;
    Future Oncol, PMID: 17280504

  123. Reduced myelotoxicity with sustained tumor concentration of radioimmunoconjugates in rats after extracorporeal depletion.
    M, årtensson, Linda; Nilsson, Rune; Ohlsson, Tomas; Sj, ögren, Hans-Olov; Strand, Sven-Erik; Tennvall, Jan;
    J Nucl Med, PMID: 17268025

  124. Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas.
    Kneifel, Stefan; Bernhardt, Peter; Uusij, ärvi, Helena; Good, Stephan; Plasswilm, Ludwig; Buitrago-T, éllez, Carlos; M, üller-Brand, Jan; M, äcke, Helmut; Merlo, Adrian;
    Eur J Nucl Med Mol Imaging, PMID: 17265035

  125. Renaissance of targeting molecules for melanoma.
    Dadachova, Ekaterina; Casadevall, Arturo;
    Cancer Biother Radiopharm, PMID: 17257069

  126. [Neuroendocrine tumors of the gastrointestinal tract]
    Arnold, C;
    Praxis (Bern 1994), PMID: 17256557

  127. [Targeted radionuclide therapy for patients with metastatic medullary thyroid carcinoma]
    Gao, Zai-rong; An, Rui; Zhang, Yong-xue; Biersack, Hans J;
    Zhonghua Zhong Liu Za Zhi, PMID: 17236560

  128. Beta radiation exposure of medical staff and implications for extremity dose monitoring.
    Rimpler, A; Barth, I;
    Radiat Prot Dosimetry, PMID: 17223637

  129. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
    Song, Hong; Du, Yong; Sgouros, George; Prideaux, Andrew; Frey, Eric; Wahl, Richard L;
    J Nucl Med, PMID: 17204712

  130. Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma.
    Fortin, Marc-Andr; é; Orlova, Anna; Malmstr, öm, Per-Uno; Tolmachev, Vladimir;
    Int J Mol Med, PMID: 17203203

  131. IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation.
    Paganelli, Giovanni; Ferrari, Mahila; Cremonesi, Marta; De Cicco, Concetta; Galimberti, Viviana; Luini, Alberto; Veronesi, Paolo; Fiorenza, Maurizio; Carminati, Paolo; Zanna, Claudio; Orecchia, Roberto; Veronesi, Umberto;
    Breast, PMID: 17174093

  132. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
    Santos, Edgardo S; Kharfan-Dabaja, Mohamed A; Ayala, Ernesto; Raez, Luis E;
    Leuk Lymphoma, PMID: 17169792

  133. Management and prevention of adverse effects related to treatment of liver tumours with 90Y microspheres.
    Szyszko, Teresa; Al-Nahhas, Adil; Tait, Paul; Rubello, D; Canelo, Ruben; Habib, Nagy; Jiao, Long; Wasan, Harpreet; Bansi, D; Thillainayagam, A; Nijran, K; Stamp, G; O'Rourke, E;
    Nucl Med Commun, PMID: 17159545

  134. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko, Teresa; Al-Nahhas, Adil; Canelo, Ruben; Habib, Nagy; Jiao, Long; Wasan, Harpreet; Pagou, Margarita; Tait, Paul;
    Nucl Med Commun, PMID: 17159544

  135. Gateways to clinical trials.
    Bay, és, M; Rabasseda, X; Prous, J R;
    Methods Find Exp Clin Pharmacol, PMID: 17136234

  136. Implications of the blood-brain barrier in primary central nervous system lymphoma.
    Jahnke, Kristoph; Doolittle, Nancy D; Muldoon, Leslie L; Neuwelt, Edward A;
    Neurosurg Focus, PMID: 17134113

  137. Radiopharmaceutical management of 90Y/111In labeled antibodies: shielding and quantification during preparation and administration.
    van Hemert, Formijn J; Sloof, Gerrit W; Schimmel, Kirsten J M; Vervenne, Walter L; van Eck-Smrr, Berthe L F; Busemann-Sokole, Ellinor;
    Ann Nucl Med, PMID: 17134028

  138. [90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab]
    Aurer, Igor; Hui, ć, Drazen; Zuvi, ć, Marijan; Sever-Prebili, ć, Mirjana; Ajdukovi, ć, Radmila; Radman, Ivo; Skare-Librenjak, Ljubica; Ostoji, ć-Kolonić, Slobodanka; Labar, Boris;
    Lijec Vjesn, PMID: 17087138

  139. Comparison between drug-eluting stents and beta-radiation for the treatment of diffuse in-stent restenosis: clinical and angiographic outcomes.
    Zavalloni, Dennis; Belli, Guido; Rossi, Marco L; Scatturin, Melania; Morenghi, Emanuela; Catalano, Gianpiero; Tosi, Giovanni; Gasparini, Gabriele L; Pagnotta, Paolo; Presbitero, Patrizia;
    Am Heart J, PMID: 17070155

  140. Therapeutic status of radiosynoviorthesis of the knee with yttrium [90Y] colloid in rheumatoid arthritis and related indications.
    Kampen, W U; Voth, M; Pinkert, J; Krause, A;
    Rheumatology (Oxford), PMID: 17065191

  141. A new internal pair production branching ratio of 90Y: the development of a non-destructive assay for 90Y and 90Sr.
    Selwyn, R G; Nickles, R J; Thomadsen, B R; DeWerd, L A; Micka, J A;
    Appl Radiat Isot, PMID: 17045483

  142. Lutetium-177-labeled gastrin releasing peptide receptor binding analogs: a novel approach to radionuclide therapy.
    Panigone, S; Nunn, A D;
    Q J Nucl Med Mol Imaging, PMID: 17043628

  143. Monte Carlo dose voxel kernel calculations of beta-emitting and Auger-emitting radionuclides for internal dosimetry: A comparison between EGSnrcMP and EGS4.
    Strigari, Lidia; Menghi, Enrico; D'Andrea, Marco; Benassi, Marcello;
    Med Phys, PMID: 17022234

  144. Experimental determination of the radial dose function of 90Sr/90Y IVBT sources.
    Holmes, Shannon M; DeWerd, Larry A; Micka, John A;
    Med Phys, PMID: 17022216

  145. A theoretical investigation into post-operative, intracavitary beta therapy of high-grade glioblastomas using yttrium-90.
    Stefanou, S S; Sparks, R B; Dale, R G;
    Phys Med Biol, PMID: 17019045

  146. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide.
    McBride, William J; Zanzonico, Pat; Sharkey, Robert M; Nor, én, Carl; Karacay, Habibe; Rossi, Edmund A; Losman, Michele J; Brard, Pierre-Yves; Chang, Chien-Hsing; Larson, Steven M; Goldenberg, David M;
    J Nucl Med, PMID: 17015905

  147. Gateways to clinical trials.
    Bayes, M; Rabasseda, X; Prous, J R;
    Methods Find Exp Clin Pharmacol, PMID: 17003851

  148. Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
    Moosmayer, Dieter; Berndorff, Dietmar; Chang, Chien-Hsing; Sharkey, Robert M; Rother, Axel; Borkowski, Sandra; Rossi, Edmund A; McBride, William J; Cardillo, Thomas M; Goldenberg, David M; Dinkelborg, Ludger M;
    Clin Cancer Res, PMID: 17000696

  149. Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.
    Lehmann, Joerg; DeNardo, Gerald L; Yuan, Aina; Shen, Sui; O'Donnell, Robert T; Richman, Carol M; DeNardo, Sally J;
    Int J Radiat Oncol Biol Phys, PMID: 16965873

  150. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
    Macklis, Roger M; Pohlman, Brad;
    Int J Radiat Oncol Biol Phys, PMID: 16965871

  151. Estimation of radiation dose at various depths for commonly used radionuclides in radiosynoviorthesis in a tissue equivalent material.
    Tandon, Pankaj; Malpani, B L; Venkatesh, Meera; Bhatt, B C;
    Med Phys, PMID: 16964849

  152. Reducing renal uptake of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues.
    Miao, Yubin; Fisher, Darrell R; Quinn, Thomas P;
    Nucl Med Biol, PMID: 16934691

  153. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients.
    Stubbs, Richard S; O'Brien, Inga; Correia, Mauro M;
    ANZ J Surg, PMID: 16916386

  154. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.
    Sangro, Bruno; Bilbao, Jose I; Boan, Jose; Martinez-Cuesta, Antonio; Benito, Alberto; Rodriguez, Javier; Panizo, Angel; Gil, Belen; Inarrairaegui, Mercedes; Herrero, Ignacio; Quiroga, Jorge; Prieto, Jesus;
    Int J Radiat Oncol Biol Phys, PMID: 16904840

  155. Gateways to clinical trials.
    Bayes, M; Rabasseda, X; Prous, J R;
    Methods Find Exp Clin Pharmacol, PMID: 16894408

  156. Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
    Glatting, Gerhard; M, üller, Marguerite; Koop, Bernd; Hohl, Kathrin; Friesen, Claudia; Neumaier, Bernd; Berrie, Eleanor; Bird, Pru; Hale, Geoffrey; Blumstein, Norbert M; Waldmann, Herman; Bunjes, Donald; Reske, Sven N;
    J Nucl Med, PMID: 16883014

  157. Biological optimization of heterogeneous dose distributions in systemic radiotherapy.
    Strigari, Lidia; D'Andrea, Marco; Maini, Carlo Ludovico; Sciuto, Rosa; Benassi, Marcello;
    Med Phys, PMID: 16872093

  158. Radioimmunotherapy: Principles, current trends and future directions.
    Karagiannis, Tom C;
    Hell J Nucl Med, PMID: 16868640

  159. Successful chemotherapy and 90Y-DOTATOC in a patient with mediastinal highly aggressive neuroendocrine carcinoma.
    Fazio, Nicola; Grana, Chiara; Pelosi, Giuseppe; Torrisi, Rosalba; Di Meglio, Giovanni; Tradati, Nicoletta; Lorizzo, Katia; De Braud, Filippo;
    Acta Oncol, PMID: 16864182

  160. [Metabolic radiotherapy for gastroenteropancreatic endocrine tumors using radiolabeled somatostatin]
    Borson-Chazot, F;
    Ann Endocrinol (Paris), PMID: 16840910

  161. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
    Dav, ì, M V; Bodei, L; Francia, G; Bartolomei, M; Oliani, C; Scilanga, L; Reghellin, D; Falconi, M; Paganelli, G; Lo Cascio, V; Ferdeghini, M;
    J Endocrinol Invest, PMID: 16840837

  162. Yttrium 90 ibritumomab tiuxetan in lymphoma.
    Cheung, Matthew C; Haynes, Adam E; Stevens, Adrienne; Meyer, Ralph M; Imrie, Kevin;
    Leuk Lymphoma, PMID: 16840185

  163. Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma.
    Weigert, Oliver; Illidge, Tim; Hiddemann, Wolfgang; Dreyling, Martin;
    Cancer, PMID: 16826593

  164. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: The MIRD equations for dose calculations.
    Gulec, Seza A; Mesoloras, Geraldine; Stabin, Michael;
    J Nucl Med, PMID: 16818957

  165. Gateways to clinical trials.
    Bayes, M; Rabasseda, X; Prous, J R;
    Methods Find Exp Clin Pharmacol, PMID: 16810345

  166. 90Y-Ibritumomab tiuxetan: new drug, interesting concept, and encouraging in practice.
    Otte, Andreas;
    Nucl Med Commun, PMID: 16794521

  167. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy.
    Justice, Terry E; Martenson, James A; Wiseman, Gregory A; Witzig, Thomas E;
    Cancer, PMID: 16770786

  168. A revision of Bremia graminicola.
    Thines, Marco; G, öker, Markus; Spring, Otmar; Oberwinkler, Franz;
    Mycol Res, PMID: 16766172

  169. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki, Sophia; Strauss, Ludwig G; Georgoulias, Vassilios; Eisenhut, Michael; Haberkorn, Uwe; Dimitrakopoulou-Strauss, Antonia;
    Eur J Nucl Med Mol Imaging, PMID: 16763820

  170. Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
    Johnston, Patrick B; Bondly, Cara; Micallef, Ivana N M;
    Expert Rev Anticancer Ther, PMID: 16761929

  171. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.
    Forrer, Flavio; Waldherr, Christian; Maecke, Helmut R; Mueller-Brand, Jan;
    Anticancer Res, PMID: 16739341

  172. Preparation of a radionuclide/gel formulation for localised radiotherapy to a wide range of organs and tissues.
    Holte, O; Skretting, A; T, ønnesen, H H; Karlsen, J;
    Pharmazie, PMID: 16724539

  173. 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3 years' experience.
    Hubalewska-Dydejczyk, A; Fr, öss-Baron, K; Miko, łajczak, R; Maecke, H R; Huszno, B; Pach, D; Sowa-Staszczak, A; Janota, B; Szybi, ński, P; Kulig, J;
    Eur J Nucl Med Mol Imaging, PMID: 16721571

  174. In vitro and in vivo evaluation of 177Lu- and 90Y-labeled E. coli heat-stable enterotoxin for specific targeting of uroguanylin receptors on human colon cancers.
    Giblin, Michael F; Sieckman, Gary L; Shelton, Tiffani D; Hoffman, Timothy J; Forte, Leonard R; Volkert, Wynn A;
    Nucl Med Biol, PMID: 16720239

  175. In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.
    Chong, Hyun-Soon; Milenic, Diane E; Garmestani, Kayhan; Brady, Erik D; Arora, Hans; Pfiester, Candice; Brechbiel, Martin W;
    Nucl Med Biol, PMID: 16720237

  176. Comparison of extraarticular leakage values of radiopharmaceuticals used for radionuclide synovectomy.
    Gedik, Gonca Kara; U, ğur, Omer; Atilla, B; ülent; Pekmezci, Murat; Yildirim, Mustafa; Seven, Bedri; Varo, ğlu, Erhan;
    Ann Nucl Med, PMID: 16715948

  177. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience.
    Kennedy, Andrew S; Coldwell, Douglas; Nutting, Charles; Murthy, Ravi; Wertman, Daniel E; Loehr, Stephen P; Overton, Carroll; Meranze, Steven; Niedzwiecki, Jerry; Sailer, Scott;
    Int J Radiat Oncol Biol Phys, PMID: 16690429

  178. [(111)In]DOTATOC as a dosimetric substitute for kidney dosimetry during [(90)Y]DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach.
    Stahl, Alexander; Schachoff, Sylvia; Beer, Ambros; Winter, Anna; Wester, Hans J; ürgen; Scheidhauer, Klemens; Schwaiger, Markus; Wolf, Ingo;
    Eur J Nucl Med Mol Imaging, PMID: 16645839

  179. Radiation synovectomy with yttrium-90 for persisting arthritis has direct harmful effects on human cartilage that cannot be prevented by co-administration of glucocorticoids: an in vitro study.
    Jahangier, Z N; Jacobs, K M G; Bijlsma, J W J; Lafeber, F P J G;
    Ann Rheum Dis, PMID: 16644786

  180. Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids.
    Jahangier, Z N; Jacobs, J W G; Kraan, M C; Wenting, M J G; Smeets, T J; Bijlsma, J W J; Lafeber, F P J G; Tak, P P;
    Ann Rheum Dis, PMID: 16627543

  181. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.
    Bushnell, David;
    J Gastrointest Surg, PMID: 16622984

  182. In situ long-term monitoring system for radioactive contaminants.
    Klein, D M; Yukihara, E G; McKeever, S W S; Durham, J S; Akselrod, M S;
    Radiat Prot Dosimetry, PMID: 16606659

  183. Half-life evaluations for 3H, 90Sr, and 90Y.
    MacMahon, Desmond;
    Appl Radiat Isot, PMID: 16600605

  184. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
    Kelly, Marcus P; Lee, Fook T; Smyth, Fiona E; Brechbiel, Martin W; Scott, Andrew M;
    J Nucl Med, PMID: 16595507

  185. Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
    Madsen, Mark T; Bushnell, David L; Juweid, Malik E; Menda, Yusuf; O'Dorisio, M Sue; O'Dorisio, Thomas; Besse, Ian M;
    J Nucl Med, PMID: 16595501

  186. Activity measurements of the high-energy pure beta-emitters 89Sr and 90Y by the TDCR efficiency calculation technique.
    Simpson, B R S; Van Wyngaardt, W M;
    Appl Radiat Isot, PMID: 16584886

  187. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
    Pagel, John M; Lin, Yukang; Hedin, Nathan; Pantelias, Anastasia; Axworthy, Donald; Stone, Diane; Hamlin, Don K; Wilbur, D Scott; Press, Oliver W;
    Blood, PMID: 16556891

  188. 90Sr in deciduous teeth from 1950 to 2002: the Swiss experience.
    Froidevaux, P; Geering, Jean-Jacques; Valley, J-F;
    Sci Total Environ, PMID: 16546237

  189. [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas]
    Setoain, X; L, ópez-Guillermo, A; Ruiz, A; Pons, F;
    Rev Esp Med Nucl, PMID: 16540015

  190. [Radioimmunotherapy for non-Hodgkin lymphoma: historical development and current status]
    Emmanouilides, C;
    Rev Esp Med Nucl, PMID: 16540013

  191. Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors.
    Valkema, Roelf; Pauwels, Stanislas; Kvols, Larry K; Barone, Raffaella; Jamar, Francois; Bakker, Willem H; Kwekkeboom, Dik J; Bouterfa, Hakim; Krenning, Eric P;
    Semin Nucl Med, PMID: 16517236

  192. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
    van Eerd, Julli; ëtte E M; Vegt, Erik; Wetzels, Jack F M; Russel, Frans G M; Masereeuw, Rosalinde; Corstens, Frans H M; Oyen, Wim J G; Boerman, Otto C;
    J Nucl Med, PMID: 16513623

  193. Nuclear data for production of the therapeutic radionuclides 32P, 64Cu, 67Cu, 89Sr, 90Y and 153Sm via the (n,p) reaction: evaluation of excitation function and its validation via integral cross-section measurement using a 14 MeV d(Be) neutron source.
    Al-Abyad, M; Spahn, I; Sud, ár, S; Morsy, M; Comsan, M N H; Csikai, J; Qaim, S M; Coenen, H H;
    Appl Radiat Isot, PMID: 16497506

  194. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
    Norenberg, Jeffrey P; Krenning, Boudewijn J; Konings, Inge R H M; Kusewitt, Donna F; Nayak, Tapan K; Anderson, Tamara L; de Jong, Marion; Garmestani, Kayhan; Brechbiel, Martin W; Kvols, Larry K;
    Clin Cancer Res, PMID: 16467104

  195. In vitro evaluation of no carrier added, carrier added and cross-complexed [90Y]-EDTMP provides evidence for a novel "foreign carrier theory".
    Toegel, Stefan; Mien, Leonhard-Key; Wadsak, Wolfgang; Eidherr, Harald; Viernstein, Helmut; Kluger, Rainer; Ettlinger, Dagmar; Kletter, Kurt; Dudczak, Robert; Mitterhauser, Markus;
    Nucl Med Biol, PMID: 16459264

  196. Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.
    Zenz, Thorsten; Schlenk, Richard F; Glatting, Gerhard; Neumaier, Bernd; Blumstein, Norbert; Buchmann, Inga; von Harsdorf, Stephanie; Ringhoffer, Mark; Wiesneth, Markus; Keller, Frieder; Kotzerke, J; örg; R, öttinger, Erwin; Stilgenbauer, Stephan; D, öhner, Hartmut; Reske, Sven N; Bunjes, Donald;
    J Nucl Med, PMID: 16455634

  197. Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission.
    Verheijen, Ren; é H; Massuger, Leon F; Benigno, Benedict B; Epenetos, Agamemnon A; Lopes, Alberto; Soper, John T; Markowska, Janica; Vyzula, Rostislav; Jobling, Tom; Stamp, Gordon; Spiegel, Gregory; Thurston, Dennis; Falke, Theo; Lambert, Joanna; Seiden, Michael V;
    J Clin Oncol, PMID: 16446329

  198. (99m)Tc-EDDA/HYNIC-octreotate - a new radiotracer for detection and staging of NET: a case of metastatic duodenal carcinoid.
    Hubalewska-Dydejczyk, Alicja; Szybi, ński, Piotr; Fr, öss-Baron, Katarzyna; Mikolajczak, Renata; Huszno, Bohdan; Sowa-Staszczak, Anna;
    Nucl Med Rev Cent East Eur, PMID: 16437406

  199. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki, Sophia; Strauss, Ludwig G; Georgoulias, Vassilios; Schuhmacher, Jochen; Haberkorn, Uwe; Karkavitsas, Nikolaos; Dimitrakopoulou-Strauss, Antonia;
    Eur J Nucl Med Mol Imaging, PMID: 16437218

  200. Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
    Masters, Gregg R; Berger, Marc A; Albone, Earl F;
    Gynecol Oncol, PMID: 16434088

  201. Localized internal radiotherapy with 90Y particles embedded in a new thermosetting alginate gel: a feasibility study in pigs.
    Holte, Oyvind; Skretting, Arne; Bach-Gansmo, Tore; Hol, Per Kristian; Johnsrud, Kjersti; T, ønnesen, Hanne Hjorth; Karlsen, Jan;
    Nucl Med Commun, PMID: 16404233

  202. Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC.
    Ferrari, Mahila; Cremonesi, Marta; Bartolomei, Mirco; Bodei, Lisa; Chinol, Marco; Fiorenza, Maurizio; Tosi, Giampiero; Paganelli, Giovanni;
    J Nucl Med, PMID: 16391194

  203. Relationship of 99mtechnetium labelled macroaggregated albumin (99mTc-MAA) uptake by colorectal liver metastases to response following Selective Internal Radiation Therapy (SIRT).
    Dhabuwala, Atul; Lamerton, Prue; Stubbs, Richard S;
    BMC Nucl Med, PMID: 16375764

  204. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski, Robert J; Thurston, Kenneth G; Goin, James E; Wong, Ching-Yee O; Gates, Vanessa L; Van Buskirk, Mark; Geschwind, Jean-Francois H; Salem, Riad;
    J Vasc Interv Radiol, PMID: 16371530

  205. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival.
    Salem, Riad; Lewandowski, Robert J; Atassi, Bassel; Gordon, Stuart C; Gates, Vanessa L; Barakat, Omar; Sergie, Ziad; Wong, Ching-Yee O; Thurston, Kenneth G;
    J Vasc Interv Radiol, PMID: 16371529

  206. [Radioisotope therapy with somatostatin analogues in neuroendocrine tumours (case report)]
    Kunikowska, Jolanta; Kr, ólicki, Leszek; Cwik, ła, Jaros; ław; Miko, łajczak, Renata; Pawlak, Dariusz; Korsak, Agnieszka; Koz, łowicz, Izabela; Poprawski, Jakub; P, łazińska, Maria; Kobylecka, Ma; łgorzata; Maczewska, Joanna; Zyci, ńska, Katarzyna; Wardyn, Kazimierz;
    Endokrynol Pol, PMID: 16335674

  207. Intercomparison of activity measurements for beta-emitters in Swiss nuclear medicine laboratories.
    Wastiel, Claude; Valley, Jean-Fran; çois; Delaloye, Angelika Bischof; Leresche, Michel; Linder, Reto; Sassowsky, Manfred; Bochud, Fran; çois O;
    J Nucl Med Technol, PMID: 16322126

  208. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
    Fietz, T; Uharek, L; Gentilini, C; Muessig, A; Rieger, K; Marinets, O; Sandrock, D; Munz, D L; Glass, B; Thiel, E; Blau, I W;
    Leuk Lymphoma, PMID: 16321828

  209. Monte Carlo modeling of the response of NRC's 90Sr/90Y primary beta standard.
    Selvam, T Palani; Saull, P R B; Rogers, D W O;
    Med Phys, PMID: 16279060

  210. Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
    Vallera, Daniel A; Brechbiel, Martin W; Burns, Linda J; Panoskaltsis-Mortari, Angela; Dusenbery, Katie E; Clohisy, Dennis R; Vitetta, Ellen S;
    Clin Cancer Res, PMID: 16278417

  211. Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
    Forero, Andres; Meredith, Ruby F; Khazaeli, M B; Shen, Sui; Grizzle, William E; Carey, Delicia; Busby, Elizabeth; LoBuglio, Albert F; Robert, Francisco;
    Cancer Biother Radiopharm, PMID: 16248762

  212. Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
    Kotzerke, J; Bunjes, D; Scheinberg, D A;
    Bone Marrow Transplant, PMID: 16247432

  213. Stability of radioactive colloids for radiation synovectomy: influence of X-ray contrast agents, anaesthetics and glucocorticoids in vitro.
    Schom, äcker, Klaus; Dietlein, Markus; M, ödder, Gynter; Boddenberg-P, ätzold, Barbara; Zimmermanns, Beate; Fischer, Thomas; Schicha, Harald;
    Nucl Med Commun, PMID: 16208182

  214. The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma.
    Cheson, Bruce D;
    BioDrugs, PMID: 16207072

  215. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
    Vallabhajosula, Shankar; Goldsmith, Stanley J; Kostakoglu, Lale; Milowsky, Mathew I; Nanus, David M; Bander, Neil H;
    Clin Cancer Res, PMID: 16203821

  216. Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
    DeNardo, Sally J; Richman, Carol M; Albrecht, Huguette; Burke, Patricia A; Natarajan, Arut; Yuan, Aina; Gregg, Jeff P; O'Donnell, R T; DeNardo, Gerald L;
    Clin Cancer Res, PMID: 16203820

  217. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
    Jacobs, Samuel A; Vidnovic, Nicholas; Joyce, Judith; McCook, Barry; Torok, Frank; Avril, Norbert;
    Clin Cancer Res, PMID: 16203814

  218. Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy.
    M, årtensson, Linda; Wang, Zhongmin; Nilsson, Rune; Ohlsson, Tomas; Senter, Peter; Sj, ögren, Hans-Olov; Strand, Sven-Erik; Tennvall, Jan;
    Clin Cancer Res, PMID: 16203809

  219. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
    Lee, Fook T; Mountain, Angela J; Kelly, Marcus P; Hall, Cathrine; Rigopoulos, Angela; Johns, Terrance G; Smyth, Fiona E; Brechbiel, Martin W; Nice, Edouard C; Burgess, Antony W; Scott, Andrew M;
    Clin Cancer Res, PMID: 16203806

  220. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
    DeNardo, Gerald L; Tobin, Evan; Chan, Kaylund; Bradt, Bonnie M; DeNardo, Sally J;
    Clin Cancer Res, PMID: 16203805

  221. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy.
    McStay, Mary K G; Maudgil, Dave; Williams, Martin; Tibballs, Jonathan M; Watkinson, Anthony F; Caplin, Martyn E; Buscombe, John R;
    Radiology, PMID: 16192318

  222. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.
    Parry, Renate; Schneider, Doug; Hudson, Debra; Parkes, Debbie; Xuan, Jian-Ai; Newton, Alicia; Toy, Pam; Lin, Rick; Harkins, Rick; Alicke, Bruno; Biroc, Sandra; Kretschmer, Peter J; Halks-Miller, Meredith; Klocker, Helmut; Zhu, Ying; Larsen, Brent; Cobb, Ronald R; Bringmann, Peter; Roth, Georg; Lewis, Jason S; Dinter, Harald; Parry, Gordon;
    Cancer Res, PMID: 16166318

  223. Current status of cancer therapy with radiolabeled monoclonal antibody.
    Oriuchi, Noboru; Higuchi, Tetsuya; Hanaoka, Hirofumi; Iida, Yasuhiko; Endo, Keigo;
    Ann Nucl Med, PMID: 16164191

  224. [Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives]
    Schom, äcker, K; Dietlein, M; Schnell, R; Pinkert, J; Eschner, W; Zimmermanns, B; Fischer, T; Engert, A; Schicha, H;
    Nuklearmedizin, PMID: 16163413

  225. Complications in 90Y radiation synovectomy.
    Chadzopoulos, Dimitrios; Badiavas, Kosmas;
    Hell J Nucl Med, PMID: 16142259

  226. Monoclonal antibodies: old and new trends in breast cancer imaging and therapeutic approach.
    Stipsanelli, Ekaterini; Valsamaki, Pipitsa;
    Hell J Nucl Med, PMID: 16142251

  227. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody.
    Richman, Carol M; Denardo, Sally J; O'Donnell, Robert T; Yuan, Aina; Shen, Sui; Goldstein, Desiree S; Tuscano, Joseph M; Wun, Ted; Chew, Helen K; Lara, Primo N; Kukis, David L; Natarajan, Arutselvan; Meares, Claude F; Lamborn, Kathleen R; DeNardo, Gerald L;
    Clin Cancer Res, PMID: 16115934

  228. A novel platform for radioimmunotherapy: extracorporeal depletion of biotinylated and 90Y-labeled rituximab in patients with refractory B-cell lymphoma.
    Lind, én, Ola; Kurkus, Jan; Garkavij, Michael; Cavallin-St, åhl, Eva; Ljungberg, Michael; Nilsson, Rune; Ohlsson, Tomas; Sandberg, Bengt; Strand, Sven-Erik; Tennvall, Jan;
    Cancer Biother Radiopharm, PMID: 16114994

  229. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides.
    Miller, William H; Hartmann-Siantar, Christine; Fisher, Darrell; Descalle, Marie-Anne; Daly, Tom; Lehmann, Joerg; Lewis, Michael R; Hoffman, Timothy; Smith, Jeff; Situ, Peter D; Volkert, Wynn A;
    Cancer Biother Radiopharm, PMID: 16114992

  230. Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging.
    Wong, Ching-Yee Oliver; Qing, Feng; Savin, Michael; Campbell, Janice; Gates, Vanessa L; Sherpa, Kanchi M; Lewandowski, Robert J; Nagle, Conrad; Salem, Riad;
    J Vasc Interv Radiol, PMID: 16105922

  231. The effect of catheter-directed CT angiography on yttrium-90 radioembolization treatment of hepatocellular carcinoma.
    Rhee, Thomas K; Omary, Reed A; Gates, Vanessa; Mounajjed, Taofic; Larson, Andrew C; Barakat, Omar; Sato, Kent T; Mulcahy, Mary; Gordon, Stuart; Lewandowski, Robert J; Salem, Riad;
    J Vasc Interv Radiol, PMID: 16105920

  232. Radiobiological monitoring of striped field mouse populations in the Moscow recreation forest "Kuzminki".
    Osipov, A N; Sypin, V D; Polsky, O G; Ilyinov, A N; Ryazanov, I A; Elakov, A L; Afonin, V Yu; Egorov, V G;
    J Environ Radioact, PMID: 16099081

  233. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    Ringhoffer, Mark; Blumstein, Norbert; Neumaier, Bernd; Glatting, Gerhard; von Harsdorf, Stephanie; Buchmann, Inga; Wiesneth, Markus; Kotzerke, J; örg; Zenz, Thorsten; Buck, Andreas K; Schauwecker, Peter; Stilgenbauer, Stephan; D, öhner, Hartmut; Reske, Sven N; Bunjes, Donald;
    Br J Haematol, PMID: 16098076

  234. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC.
    Forrer, Flavio; Uusij, ärvi, Helena; Storch, Daniel; Maecke, Helmut R; Mueller-Brand, Jan;
    J Nucl Med, PMID: 16085587

  235. Gateways to clinical trials.
    Bay, és, M; Rabasseda, X; Prous, J R;
    Methods Find Exp Clin Pharmacol, PMID: 16082422

  236. Radiolabeling and biological evaluation of DOTA-Ph-Al derivative conjugated to anti-EGFR antibody ior egf/r3 for targeted tumor imaging and therapy.
    Pnwar, Puja; Iznaga-Escobar, Normando; Mishra, Pushpa; Srivastava, Vibha; Sharma, Rakesh Kumar; Chandra, Ramesh; Mishra, Anil K;
    Cancer Biol Ther, PMID: 16082184

  237. Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.
    Lind, én, Ola; Hindorf, Cecilia; Cavallin-St, åhl, Eva; Wegener, William A; Goldenberg, David M; Horne, Heather; Ohlsson, Tomas; Stenberg, Lars; Strand, Sven-Erik; Tennvall, Jan;
    Clin Cancer Res, PMID: 16033839

  238. Treatment of hepatocellular carcinoma by means of radiopharmaceuticals.
    Lambert, Bieke; Van de Wiele, Christophe;
    Eur J Nucl Med Mol Imaging, PMID: 16032439

  239. [2-14C]Thymidine incorporation activity of stem cells in either tumor or cradle tissues in a normal or transplanted animals.
    Shigematsu, Akiyo; Yui, Joji; Hamai, Yuko; Hatori, Akiko;
    Eur J Drug Metab Pharmacokinet, PMID: 16010859

  240. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
    Nademanee, Auayporn; Forman, Stephen; Molina, Arturo; Fung, Henry; Smith, David; Dagis, Andy; Kwok, Cheuk; Yamauchi, Dave; Anderson, Anne-Line; Falk, Peter; Krishnan, Amrita; Kirschbaum, Mark; Kogut, Neil; Nakamura, Ryotaro; O'donnell, Margaret; Parker, Pablo; Popplewell, Leslie; Pullarkat, Vinod; Rodriguez, Roberto; Sahebi, Firoozeh; Smith, Eileen; Snyder, David; Stein, Anthony; Spielberger, Ricardo; Zain, Jasmine; White, Christine; Raubitschek, Andrew;
    Blood, PMID: 16002426

  241. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
    Sato, Noriko; Hassan, Raffit; Axworthy, Donald B; Wong, Karen J; Yu, Sarah; Theodore, Louis J; Lin, Yukang; Park, Luke; Brechbiel, Martin W; Pastan, Ira; Paik, Chang H; Carrasquillo, Jorge A;
    J Nucl Med, PMID: 16000290

  242. Thermoresponsive polymers as promising new materials for local radiotherapy.
    Hrub, ý, M; Subr, V; Kucka, J; Kozempel, J; Lebeda, O; Sikora, A;
    Appl Radiat Isot, PMID: 15996473

  243. Rituximab and other emerging monoclonal antibody therapies for lymphoma.
    Tobinai, Kensei;
    Expert Opin Emerg Drugs, PMID: 15989552

  244. Radiosynovectomy in hemophilic synovitis: correlation of therapeutic response and blood-pool changes.
    T, ürkmen, C; üneyt; Z, ülflkar, B; ülent; Ta, şer, Omer; Tokmak, Handan; K, ílíçoglu, Onder; Mudun, Ay; şe; Unal, Seher; Adalet, I; şik; Cantez, Sema;
    Cancer Biother Radiopharm, PMID: 15989485

  245. Radiosynoviorthesis for treatment of hemophilic hemarthrosis--Slovenian experience.
    Grmek, Marko; Milcinski, Metka; Fettich, Jurij; Benedik-Dolnicar, Majda; Brecelj, Janez;
    Cancer Biother Radiopharm, PMID: 15989481

  246. Radiotherapy of human xenograft NSCLC tumors in nude mice with a 90Y-labeled anti-tissue factor antibody.
    Wang, Baiyang; Berger, Marc; Masters, Gregg; Albone, Earl; Yang, Qifeng; Sheedy, Josephine; Kirksey, Yolanda; Grimm, Lisa; Wang, Bo; Singleton, Judith; Soltis, Daniel;
    Cancer Biother Radiopharm, PMID: 15989475

  247. Radiolabeled peptides in oncology: role in diagnosis and treatment.
    Weiner, Ronald E; Thakur, Mathew L;
    BioDrugs, PMID: 15984900

  248. Accounting for beta-particle energy loss to cortical bone via paired-image radiation transport (PIRT).
    Shah, Amish P; Rajon, Didier A; Patton, Phillip W; Jokisch, Derek W; Bolch, Wesley E;
    Med Phys, PMID: 15984687

  249. Tumor-targeting properties of 90Y- and 177Lu-labeled alpha-melanocyte stimulating hormone peptide analogues in a murine melanoma model.
    Miao, Yubin; Hoffman, Timothy J; Quinn, Thomas P;
    Nucl Med Biol, PMID: 15982579

  250. Combination of chemical separation and data treatment for 55 Fe, 63 Ni, 99 Tc, 137 Cs and 90 Sr/90Y activity determination in radioactive waste by liquid scintillation.
    Mellado, J; Taranc, ón, A; Garc, ía, J F; Rauret, G; Warwick, P;
    Appl Radiat Isot, PMID: 15963430

  251. Patient and personnel dosimetry in endovascular radiotherapy with 90Sr/90Y sources.
    Kalef-Ezra, J; Bozios, G; Tsekeris, P; Michalis, L;
    Radiat Prot Dosimetry, PMID: 15941815

  252. A special mini-extrapolation chamber for calibration of 90Sr+90Y sources.
    Oliveira, M; ércia L; Caldas, Linda V E;
    Phys Med Biol, PMID: 15930611

  253. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas.
    Coliva, Angela; Zacchetti, Alberto; Luison, Elena; Tomassetti, Antonella; Bongarzone, Italia; Seregni, Ettore; Bombardieri, Emilio; Martin, Franck; Giussani, Augusto; Figini, Mariangela; Canevari, Silvana;
    Cancer Immunol Immunother, PMID: 15926078

  254. Effect of calcium trisodium DTPA in rats with puncture wound contaminated by 90Y-chloride.
    Watanabe, N; Tanada, S; Sasaki, Y;
    Radiat Prot Dosimetry, PMID: 15899907

  255. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula, Shankar; Goldsmith, Stanley J; Hamacher, Klaus A; Kostakoglu, Lale; Konishi, Shota; Milowski, Mathew I; Nanus, David M; Bander, Neil H;
    J Nucl Med, PMID: 15872360

  256. Selective internal radiation therapy with SIR-Spheres in patients with nonresectable liver tumors.
    P, öpperl, Gabriele; Helmberger, Thomas; M, ünzing, Wolfgang; Schmid, Rupert; Jacobs, Tobias Franz; Tatsch, Klaus;
    Cancer Biother Radiopharm, PMID: 15869456

  257. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
    Wiseman, Gregory A; Witzig, Thomas E;
    Cancer Biother Radiopharm, PMID: 15869453

  258. The response of thermally and optically stimulated luminescence from Al2O3:C to high-energy heavy charged particles.
    Gaza, R; Yukihara, E G; McKeever, S W S;
    Radiat Meas, PMID: 15856574

  259. Preliminary results of nanopharmaceuticals used in the radioimmunotherapy of ovarian cancer.
    McQuarrie, Steve; Mercer, John; Syme, Alasdair; Suresh, Mavanur; Miller, Gerald;
    J Pharm Pharm Sci, PMID: 15850546

  260. Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin).
    White, Christine A;
    J Exp Ther Oncol, PMID: 15844660

  261. Calculation of photon energy deposition kernels and electron dose point kernels in water.
    Mainegra-Hing, Ernesto; Rogers, D W O; Kawrakow, Iwan;
    Med Phys, PMID: 15839340

  262. Evaluation of 90Y phosphate particles as a possible radiation synoviorthesis agent.
    Pandey, Usha; Bapat, Ketaki N; Samuel, Grace; Sarma, Haladhar D; Chaudhari, Pradeep R; Dhami, Prem S; Kannan, Ramanathan; Venkatesh, Meera;
    Nucl Med Commun, PMID: 15838430

  263. [Investigations of beta-dosimetry at two different sources for the cardiovascular brachytherapy]
    Todorovic, Manuel; Cremers, Florian; Thurmann, Horst; Schmidt, Rainer;
    Z Med Phys, PMID: 15830781

  264. 177Lu-antibody conjugates for single-cell kill of B-lymphoma cells in vitro and for therapy of micrometastases in vivo.
    Michel, Rosana B; Andrews, Philip M; Rosario, Adriane V; Goldenberg, David M; Mattes, M Jules;
    Nucl Med Biol, PMID: 15820762

  265. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumors.
    Delaunoit, Thierry; Rubin, Joseph; Neczyporenko, Florence; Erlichman, Charles; Hobday, Timothy J;
    Mayo Clin Proc, PMID: 15819288

  266. Measurements of finger doses in x-ray guided surgery, nuclear medicine and research.
    Saether, H K; Davidson, T-M; Widmark, A; W, øhni, T;
    Radiat Prot Dosimetry, PMID: 15817576

  267. Is CD20 the only target available for radionuclide therapy in lymphoproliferative disorders?
    Agazzi, A; Rocca, P; Laszlo, D; Bodei, L; Grana, C; Martinelli, G; Paganelli, G;
    Eur J Haematol, PMID: 15813923

  268. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies.
    Shen, Sui; Forero, Andres; LoBuglio, Albert F; Breitz, Hazel; Khazaeli, M B; Fisher, Darrell R; Wang, Wenquan; Meredith, Ruby F;
    J Nucl Med, PMID: 15809487

  269. Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
    Vallabhajosula, Shankar; Kuji, Ichei; Hamacher, Klaus A; Konishi, Shota; Kostakoglu, Lale; Kothari, Paresh A; Milowski, Mathew I; Nanus, David M; Bander, Neil H; Goldsmith, Stanley J;
    J Nucl Med, PMID: 15809486

  270. A phase I trial combining high-dose 90Y-labeled humanized anti-CEA monoclonal antibody with doxorubicin and peripheral blood stem cell rescue in advanced medullary thyroid cancer.
    Sharkey, Robert M; Hajjar, George; Yeldell, Dion; Brenner, Arnold; Burton, Jack; Rubin, Arnold; Goldenberg, David M;
    J Nucl Med, PMID: 15809485

  271. Angular dependence of the TL reading of thin alpha-Al2O3:C dosemeters exposed to different beta spectra.
    Mancosu, Pietro; Ripamonti, Dario; Veronese, Ivan; Cantone, Marie Claire; Giussani, Augusto; Tosi, Giampiero;
    Radiat Prot Dosimetry, PMID: 15788418

  272. Development of 131I-tositumomab.
    Lewington, Valerie;
    Semin Oncol, PMID: 15786026

  273. 90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma.
    Grillo-L, ópez, Antonio J;
    Semin Oncol, PMID: 15786025

  274. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
    Marcus, Robert;
    Semin Oncol, PMID: 15786024

  275. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert, Maren; McCook, Barry; Carr, Brian I; Geller, David A; Sheetz, Mike; Tutor, Cecilia; Amesur, Nikhil; Avril, Norbert;
    Eur J Nucl Med Mol Imaging, PMID: 15772860

  276. The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma.
    Ahmad, Jawad; Rhee, John; Carr, Brian I;
    Dig Dis Sci, PMID: 15745096

  277. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
    Lu, Sharon X; Takach, Edward J; Solomon, Marjorie; Zhu, Qing; Law, Say-Jong; Hsieh, Frank Y;
    J Pharm Sci, PMID: 15729708

  278. Theoretical study of the influence of a heterogeneous activity distribution on intratumoral absorbed dose distribution.
    Bao, Ande; Zhao, Xia; Phillips, William T; Woolley, F Ross; Otto, Randal A; Goins, Beth; Hevezi, James M;
    Med Phys, PMID: 15719971

  279. Preparation and in vitro stability of (n,gamma) yttrium-90 hydroxyapatite.
    Khalid, M; Mushtaq, A;
    Appl Radiat Isot, PMID: 15701413

  280. Effect of beta radiation on TGF-beta1 and bFGF expression in hyperplastic prostatic tissues.
    Ma, Qing-Jie; Gu, Xin-Quan; Cao, Xia; Zhao, Jie; Kong, Xiang-Bo; Li, Yu-Xin; Cai, Shan-Yu;
    Asian J Androl, PMID: 15685352

  281. A comparison of techniques for analysing 90Y-Zevalin thin-layer chromatography plates.
    O'Brien, Lesley M; Waight, Clinton C; Millar, Alistair M;
    Nucl Med Commun, PMID: 15657511

  282. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema, Roelf; Pauwels, Stanislas A; Kvols, Larry K; Kwekkeboom, Dik J; Jamar, Francois; de Jong, Marion; Barone, Raffaella; Walrand, Stephan; Kooij, Peter P M; Bakker, Willem H; Lasher, Janet; Krenning, Eric P;
    J Nucl Med, PMID: 15653656

  283. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
    Kwekkeboom, Dik J; Mueller-Brand, Jan; Paganelli, Giovanni; Anthony, Lowell B; Pauwels, Stanislas; Kvols, Larry K; O'dorisio, Thomas M; Valkema, Roelf; Bodei, Lisa; Chinol, Marco; Maecke, Helmut R; Krenning, Eric P;
    J Nucl Med, PMID: 15653653

  284. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    de Jong, Marion; Breeman, Wout A P; Valkema, Roelf; Bernard, Bert F; Krenning, Eric P;
    J Nucl Med, PMID: 15653647

  285. Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy.
    Beutler, Daniel; Avoledo, Pierino; Reubi, Jean-Claude; M, äcke, Helmut R; M, üller-Brand, Jan; Merlo, Adrian; K, ühne, Thomas;
    Cancer, PMID: 15641034

  286. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature.
    Ansell, Stephen M; Schilder, Russell J; Pieslor, Peter C; Gordon, Leo I; Emmanouilides, Christos; Vo, Katie; Czuczman, Myron S; Witzig, Thomas E; Theuer, Charles; Molina, Arturo;
    Clin Lymphoma, PMID: 15636698

  287. Dosimetric consequences of manual pullback procedure for coronary artery radiotherapy with 90Sr/90Y beta-source.
    Iftimia, Ileana; Devlin, Phillip M; Martin, Andre-Guy; Shakur, Rameen; Almonacid, Alexandra; Kazakin, Julia; Chin, Lee M; Cormack, Robert A;
    Brachytherapy, PMID: 15607153

  288. Gateways to clinical trials.
    Bay, és, M; Rabasseda, X; Prous, J R;
    Methods Find Exp Clin Pharmacol, PMID: 15605126

  289. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases.
    Bienert, Maren; McCook, Barry; Carr, Brian I; Geller, David A; Sheetz, Mike; Amesur, Nikhil; Avril, Norbert;
    Eur J Nucl Med Mol Imaging, PMID: 15599525

  290. Uncertainties in electron-absorbed fractions and lung doses from inhaled beta-emitters.
    Farf, án, Eduardo B; Bolch, Wesley E; Huston, Thomas E; Rajon, Didier A; Huh, Chulhaeng; Bolch, W Emmett;
    Health Phys, PMID: 15596988

  291. Synchronous evaluation of toxico- and pharmaco-dynamics of yttrium-90 by a novel autoradiographic procedure.
    Shigematsu, Akiyo; Kawai, Naoshi; Kuroiwa, Hiroyuki; Higashi, Noriko; Debori, Yasuyuki; Yui, Joji; Hamai, Yuko; Hatori, Akiko; Awazu, Shoji; Takeuchi, Norihiro; Yamabayashi, Hisamichi; Sato, Yuichi; Yamamoto, Takeo;
    Regul Toxicol Pharmacol, PMID: 15546676

  292. Metabolic response after intraarterial 90Y-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET.
    Wong, Ching-yee Oliver; Salem, Riad; Qing, Feng; Wong, Kin T; Barker, David; Gates, Vanessa; Lewandowski, Robert; Hill, Elizabeth A; Dworkin, Howard J; Nagle, Conrad;
    J Nucl Med, PMID: 15534060

  293. Combined treatment of glioblastoma patients with locoregional pre-targeted 90Y-biotin radioimmunotherapy and temozolomide.
    Bartolomei, M; Mazzetta, C; Handkiewicz-Junak, D; Bodei, L; Rocca, P; Grana, C; Maira, G; Sturiale, C; Villa, G; Paganelli, G;
    Q J Nucl Med Mol Imaging, PMID: 15499296

  294. Radiometals as payloads for radioimmunotherapy for lymphoma.
    DeNardo, Gerald L; Kennel, Stephen J; Siegel, Jeffry A; Denardo, Sally J;
    Clin Lymphoma, PMID: 15498149

  295. Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma.
    Micallef, Ivana N M;
    Clin Lymphoma, PMID: 15498147

  296. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma.
    Winter, Jane N;
    Clin Lymphoma, PMID: 15498146

  297. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.
    Borghaei, Hossein; Wallace, Stephen G; Schilder, Russell J;
    Clin Lymphoma, PMID: 15498145

  298. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond.
    Evens, Andrew M; Gordon, Leo I;
    Clin Lymphoma, PMID: 15498144

  299. Measurement of H'(0.07) using the plastic scintillation pulse height weighting integration method.
    Li-ye, Liu; Ji-zeng, Ma;
    Radiat Prot Dosimetry, PMID: 15494362